#cdmo

Raman Sehgal has made a career out of putting his energy— and he's got a lot of it— into building biotech outsourcing companies and the people who make them run. After years spent supporting several from within, he launched ramarketing, a firm dedicated to helping CROs, CDMOs,  CPOs, and other providers to the biotech ecosystem build their businesses, in 2009. He's also an international best-selling author (The Floundering Founder), co-founder of life sciences recruitment firm Lead Candidate,  and founder & host of the Molecule to Market podcast. On this week's episode of the Business of Biotech, Raman brings us his unique and multifaceted perspectives on the biopharma outsourcing space, the bear biotech markets, and how both are impacting the work of early- and clinical-stage biopharma leaders. 

Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Inspired to develop a treatment for Infantile Krabbe Disease, the founders of Forge Biologics picked a unique but strategic approach to funding the initiative. They built a CDMO that aims to become one of the largest on the planet in the cell and gene therapy space. On this week's episode of the Business of Biotech podcast, co-founder, President, & CEO Timothy J. Miller, Ph.D. joins us to discuss the strategy, why it was a no-brainer given the white-hot market for contract development and manufacturing space, the state of the biologics manufacturing capacity crunch,  and what companies like Forge are doing about it. 

Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

I caught up Noel earlier in the year to find out how ##CRB coped with 2020 and the impact of the pandemic, how 2021 was looking and his thoughts in terms of trends for 2021 and beyond.
A really wide ranging conversation touching on a lot of different topics relating to #LifeScience

Interview breakdown
Overview of SlateXpace and Noels background. 1:23
2020 in a word, and why? 2:39
Were they able to achieve their objectives in 2020? 3:50
When did they start planning for the Pandemic 5:12
How did the pandemic impact SlateXpace, and their sector, and what did they do to minimise the impact?  7:50
What have been the main positives for 2020? Personally, Professionally and for the Industry 9:35
Key learnings from 2020 and what would they have done differently 12:15
What does Noel see as the new normal being. 15:50
Key trends in 2021.18:30
What’s are SlateXpace plans for 2021 and beyond? 22.39
Message for those watching this 24:25

You can find out more about SlateXpace and CRB by visiting;
On LinkedIn
https://lnkd.in/eZkM56y
https://lnkd.in/ebbeKeh

Websites/Links:
www.crbgroup.com
www.slatexpace.com

You can watch Noel's previous #ChatsWithChaudhrey on CRB's #CellandGenherapy report here;
https://lnkd.in/ebbC2mx,  AND view  this and many more interviews and demos from  many other industry experts across Pharma, Bio-Pharma and Life Science on my YouTube channel RSK Life Science Media https://www.youtube.com/channel/UC9vdET2xLlGweqveW6JmQdQ


#PharmaFacilities, #CDMO, #FacilitiesOfTheFuture, #ATMP, #COVID19, #LifeSciences, #GeneTherapy, #CellTherapy,